Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

G. S. Leoung, J. Mills, P. C. Hopewell, W. Hughes, C. Wofsy

Research output: Contribution to journalArticle

Abstract

All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight · d). All 15 patients who met the entry criteria improved clinically and radiographically within 3 to 10 days after starting treatment. Repeat pulmonary function tests and gallium lung scans after 3 weeks of therapy also showed improvement. Although side effects occurred in 14 patients, in only 2 were they severe enough to require stopping therapy. Both of these patients had worsening skin rash, and dapsone-trimethoprim therapy was stopped after 10 days. When compared with trimethoprim-sulfamethoxazole or pentamidine used to treat P. carinii pneumonia in similar patients, oral dapsone-trimethoprim is at least as effective, seems to be better tolerated, and may have a lower frequency of serious side effects.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalAnnals of Internal Medicine
Volume105
Issue number1
StatePublished - 1986
Externally publishedYes

Fingerprint

Dapsone
Trimethoprim
Pneumocystis Pneumonia
Acquired Immunodeficiency Syndrome
Pentamidine
Therapeutics
Gallium
San Francisco
Respiratory Function Tests
Sulfamethoxazole Drug Combination Trimethoprim
Exanthema
General Hospitals
Body Weight
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Leoung, G. S., Mills, J., Hopewell, P. C., Hughes, W., & Wofsy, C. (1986). Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Annals of Internal Medicine, 105(1), 45-48.

Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. / Leoung, G. S.; Mills, J.; Hopewell, P. C.; Hughes, W.; Wofsy, C.

In: Annals of Internal Medicine, Vol. 105, No. 1, 1986, p. 45-48.

Research output: Contribution to journalArticle

Leoung, GS, Mills, J, Hopewell, PC, Hughes, W & Wofsy, C 1986, 'Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome', Annals of Internal Medicine, vol. 105, no. 1, pp. 45-48.
Leoung, G. S. ; Mills, J. ; Hopewell, P. C. ; Hughes, W. ; Wofsy, C. / Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. In: Annals of Internal Medicine. 1986 ; Vol. 105, No. 1. pp. 45-48.
@article{05c646f9c2424a72994ddd3a29785f1c,
title = "Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome",
abstract = "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight · d). All 15 patients who met the entry criteria improved clinically and radiographically within 3 to 10 days after starting treatment. Repeat pulmonary function tests and gallium lung scans after 3 weeks of therapy also showed improvement. Although side effects occurred in 14 patients, in only 2 were they severe enough to require stopping therapy. Both of these patients had worsening skin rash, and dapsone-trimethoprim therapy was stopped after 10 days. When compared with trimethoprim-sulfamethoxazole or pentamidine used to treat P. carinii pneumonia in similar patients, oral dapsone-trimethoprim is at least as effective, seems to be better tolerated, and may have a lower frequency of serious side effects.",
author = "Leoung, {G. S.} and J. Mills and Hopewell, {P. C.} and W. Hughes and C. Wofsy",
year = "1986",
language = "English (US)",
volume = "105",
pages = "45--48",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

AU - Leoung, G. S.

AU - Mills, J.

AU - Hopewell, P. C.

AU - Hughes, W.

AU - Wofsy, C.

PY - 1986

Y1 - 1986

N2 - All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight · d). All 15 patients who met the entry criteria improved clinically and radiographically within 3 to 10 days after starting treatment. Repeat pulmonary function tests and gallium lung scans after 3 weeks of therapy also showed improvement. Although side effects occurred in 14 patients, in only 2 were they severe enough to require stopping therapy. Both of these patients had worsening skin rash, and dapsone-trimethoprim therapy was stopped after 10 days. When compared with trimethoprim-sulfamethoxazole or pentamidine used to treat P. carinii pneumonia in similar patients, oral dapsone-trimethoprim is at least as effective, seems to be better tolerated, and may have a lower frequency of serious side effects.

AB - All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight · d). All 15 patients who met the entry criteria improved clinically and radiographically within 3 to 10 days after starting treatment. Repeat pulmonary function tests and gallium lung scans after 3 weeks of therapy also showed improvement. Although side effects occurred in 14 patients, in only 2 were they severe enough to require stopping therapy. Both of these patients had worsening skin rash, and dapsone-trimethoprim therapy was stopped after 10 days. When compared with trimethoprim-sulfamethoxazole or pentamidine used to treat P. carinii pneumonia in similar patients, oral dapsone-trimethoprim is at least as effective, seems to be better tolerated, and may have a lower frequency of serious side effects.

UR - http://www.scopus.com/inward/record.url?scp=0022652831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022652831&partnerID=8YFLogxK

M3 - Article

C2 - 2940954

AN - SCOPUS:0022652831

VL - 105

SP - 45

EP - 48

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -